GPT and metabolic dysfunction-associated steatotic liver disease: Recently, a meta-analysis of several placebo-controlled or randomized control trials that used various SGLT-2 inhibitors for the treatment of NAFLD has displayed that usage of SGLT-2 inhibitor for 24 weeks significantly decreased ALT, gamma-glutamyl transferase (GGT) level, and liver fat content, as well as body weight in NAFLD patients (152).